KA
Rating #148
Thomas Graham, Alan & Irving Kahns
Kahn Brothers Group
Portfolio value
Stocks
Performance
1 Year
+4.81%
Stock Holdings
$
%
1Y
3Y
5Y
10Y
Thomas Graham, Alan & Irving Kahns’ Portfolio: Q3 2025
Top10 stocks: 81.60% of the portfolio
Thomas Graham, Alan & Irving Kahns’ Trades: Q3 2025
Adds
New Buys
Sold Outs
Cuts
4.85ppt
0.48ppt
-1.28ppt
0.01ppt
Company Name | Share Count Chg. (%) | Price Paid | Buy Value | Portfolio % Change | |
|---|---|---|---|---|---|
1  GOOG | +89.51% | $210.20 | $13.38M | 4.85ppt | |
2  OGN | +3.63% | $9.81 | $1.24M | 0.48ppt | |
3  DIS | +0.53% | $117.78 | $244.28K | -1.28ppt | |
4  WBS | +0.28% | $59.58 | $5.00K | 0.01ppt |
Thomas Graham, Alan & Irving Kahns’ Holdings: Q3 2025
Company Name | Primary Industry | Avg. price paid  | Share Count Chg. (%) | No of shares held | Market value | Portfolio % Change | % of Ownership | Holding period | Last Transaction | |
|---|---|---|---|---|---|---|---|---|---|---|
1  C | National Banks | $52.06 | -1.13% | 876.66K | $88.98M | 16.73% 1.57ppt | 0.05% | 15 Quarters | Q3 2025 | |
- | $7.27 | +0.87% | 6.79M | $56.27M | 10.58% 0.39ppt | 0.17% | 8 Quarters | Q3 2025 | ||
3  FLG | Non-Federal Savings | $11.66 | -0.57% | 4.30M | $49.63M | 9.33% 0.13ppt | 1.04% | 4 Quarters | Q3 2025 | |
4 DIS | Misc. Amusement & Recreation | $105.10 | +0.53% | 394.52K | $45.17M | 8.49% -1.28ppt | 0.02% | 7 Quarters | Q3 2025 | |
5 OGN | Pharmaceutical Pres | $15.20 | +3.63% | 3.62M | $38.63M | 7.26% 0.48ppt | 1.39% | 18 Quarters | Q3 2025 | |
6  BP | Petroleum Refining | $35.08 | -3.88% | 1.09M | $37.41M | 7.03% 0.25ppt | 0.01% | 50 Quarters | Q3 2025 | |
7  MRK | Pharmaceutical Pres | $82.11 | -11.56% | 433.75K | $36.40M | 6.85% -0.95ppt | 0.02% | 15 Quarters | Q3 2025 | |
8 GOOG | Computer Programming & Data | $208.64 | +89.51% | 134.72K | $32.81M | 6.17% 4.85ppt | 0.00% | 2 Quarters | Q3 2025 | |
9  SEB | Wholesale-Farm Products | $3355.61 | -10.43% | 7.72K | $28.17M | 5.30% 0.34ppt | 0.80% | 50 Quarters | Q3 2025 | |
10  IDT | Telephone Communications | $42.26 | -1.06% | 392.36K | $20.52M | 3.86% -1.58ppt | 1.56% | 15 Quarters | Q3 2025 | |
11  PFE | Pharmaceutical Pres | $36.13 | -3.26% | 707.14K | $18.02M | 3.39% -0.17ppt | 0.01% | 50 Quarters | Q3 2025 | |
12  SEG | Misc. Amusement & Recreation | $22.92 | +100.00% | 583.36K | $13.37M | 2.51% 2.51ppt | 4.60% | 1 Quarter | Q3 2025 | |
13  BMY | Pharmaceutical Pres | $48.84 | -50.55% | 272.33K | $12.28M | 2.31% -2.81ppt | 0.01% | 50 Quarters | Q3 2025 | |
14  GSK | Pharmaceutical Pres | $38.40 | -60.47% | 260.84K | $11.26M | 2.12% -2.97ppt | 0.01% | 2 Quarters | Q3 2025 | |
15  PTEN | Oil & Gas Drilling | $7.76 | -1.68% | 1.89M | $9.77M | 1.84% -0.45ppt | 0.49% | 50 Quarters | Q3 2025 | |
16  MBI | Surety Insurance | $7.45 | +100.00% | 1.03M | $7.67M | 1.44% 1.44ppt | 2.08% | 1 Quarter | Q3 2025 | |
17  GNE | Combined Electric Services | $6.78 | -3.58% | 191.87K | $2.87M | 0.54% -0.53ppt | 0.73% | 15 Quarters | Q3 2025 | |
18  XOM | Petroleum Refining | $94.71 | -6.27% | 17.94K | $2.02M | 0.38% -0.03ppt | 0.00% | 50 Quarters | Q3 2025 | |
19  NVS | Pharmaceutical Pres | $76.19 | -22.44% | 14.33K | $1.84M | 0.35% -0.10ppt | 0.00% | 50 Quarters | Q3 2025 | |
20 WBS | National Banks | $55.53 | +0.28% | 30.17K | $1.79M | 0.34% 0.01ppt | 0.02% | 15 Quarters | Q3 2025 |
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.